The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn&#39;s disease - An interview with David A Schwartz, 13 June 2007

Código QR

The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn&#39;s disease - An interview with David A Schwartz, 13 June 2007

David A SchwartzVanderbilt University Medical Center, Nashville, TN, USAContext: Certolizumab pegol (CDP 870) is a new anti-tumor necrosis factor (TNF) therapy currently in development for the treatment of Crohn&rsquo;s disease, rheumatoid arthritis, and psoriasis. Certolizumab pegol is the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	David A Schwartz
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/08346a070d204e8d80f6d9eaca6f7195
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
por: Marin J, et al.
Publicado: (2018)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
por: Acosta-Felquer ML, et al.
Publicado: (2016)

Prefilled certolizumab pegol (Cimzia&reg;) syringes for self-use in the treatment of rheumatoid arthritis
por: J Rosa, et al.
Publicado: (2010)

The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
por: Roy Fleischmann
Publicado: (2009)

Paradoxical SAPHO syndrome observed during anti-TNF-α therapy for Crohn's disease
por: Amano H, et al.
Publicado: (2017)

Regional simulation with the PRECIS Model
por: Falvey,Mark
Publicado: (2012)

Précis D'économie et de législation financières
por: Laufenburger, Henry, b, 1897
Publicado: (1943)

Precis de Droit fiscal ( tout les impats)
por: Mégret, Jean
Publicado: (1949)

Certolizumab in the long-term treatment of rheumatoid arthritis
por: Scott DL, et al.
Publicado: (2011)

Endogenous antisense RNA curbs CD39 expression in Crohn’s disease
por: Rasika P. Harshe, et al.
Publicado: (2020)

Some Reflections on Children’s Media Cultures: An Interview with David Buckingham
por: Thibaut Clément, et al.
Publicado: (2020)

Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients
por: Santos-Moreno P, et al.
Publicado: (2021)

An Interview with David Kreps: Author of Against Nature: The Metaphysics of Information Systems
por: David Kreps
Publicado: (2018)

Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
por: Petkau JM, et al.
Publicado: (2016)

Evaluation of changes in intestinal microbiota in Crohn’s disease patients after anti-TNF alpha treatment
por: Laura Sanchis-Artero, et al.
Publicado: (2021)

Leptin induces TNFα-dependent inflammation in acquired generalized lipodystrophy and combined Crohn’s disease
por: Jörn F. Ziegler, et al.
Publicado: (2019)

Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease
por: Tsvetelina Veselinova Velikova, et al.
Publicado: (2018)

Using Blended and Virtual Schwartz Center Rounds® to Support Maternity Staff in Ireland During the Covid-19 Pandemic
por: Jean Doherty, et al.
Publicado: (2021)

Review. Successful family language policy: Parents, children and educators in interaction, edited by Mila Schwartz and Anna Verschik
por: Francesca Walls
Publicado: (2015)

Experiencia local con natalizumab en pacientes con enfermedad de Crohn refractaria a anti-TNF: Casos clínicos
por: Fluxá,Daniela, et al.
Publicado: (2017)

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
por: Klamroth R, et al.
Publicado: (2021)

The path to precision medicine for MS, from AI to patient recruitment: an interview with Mauricio Farez and Helen Onuorah
Publicado: (2021)

Journal of Crohn's and colitis

Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients
por: Martyna Szczubełek, et al.
Publicado: (2021)

Interactions of primaquine and chloroquine with PEGylated phosphatidylcholine liposomes
por: Andang Miatmoko, et al.
Publicado: (2021)

Crohn’s Disease Ocular Manifestations
por: Koev Kr.
Publicado: (2014)

David Gascoyne
por: Santiago Matías
Publicado: (2012)

David Hume
Publicado: (2004)

Fabrication of fluorescent nanospheres by heating PEGylated tetratyrosine nanofibers
por: Enrico Gallo, et al.
Publicado: (2021)

Acta No. 39
por: Banco Central de Chile
Publicado: (2019)

Benjamín I. SCHWARTZ (ed.), <em>Reflections on the May Fourth Movement: a symposium Cambridge, Mass.</em>, Harvard University Press, 1972, Harvard East Asian Monographes. Nº 44, 132 pp.
por: - -
Publicado: (1980)

David Lynch Sprawls
por: Richard Martin
Publicado: (2020)

The impact of PEGylation patterns on the in vivo biodistribution of mixed shell micelles
por: Gao H, et al.
Publicado: (2013)

PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy
por: Byeon HJ, et al.
Publicado: (2015)

Effects of PEGylation on capture of dextran-coated magnetic nanoparticles in microcirculation
por: Chiu CY, et al.
Publicado: (2019)

Biennial report (14 June 2008 - 1 June 2010)
Publicado: (2014)

Capsule endoscopy in the diagnosis of Crohn’s disease
por: Niv Y
Publicado: (2013)

Adalimumab for the treatment of Crohn&rsquo;s disease
por: Andrea Cassinotti, et al.
Publicado: (2008)

An alternative splicing signature in human Crohn’s disease
por: Daowei Li, et al.
Publicado: (2021)